Press Release on the Financial Results of the Company for the quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 05 Aug 2026, 04:16 PM IST · BSE ID: c7a831ff-07ff-4289-9f9c-ee11a71cd769
View Original BSE Filing (PDF)
💡
In Simple Terms
Neuland Laboratories reported significantly higher income and profits for the quarter ending June 2026.
🤖 AI Summary
- Neuland Laboratories reported Total Income of Rs. 650.1 crore for Q1 FY27, up 116.3% YoY.
- EBITDA increased to Rs. 231.1 crore in Q1 FY27, showing a 448.2% growth year-over-year.
- Profit After Tax (PAT) for Q1 FY27 was Rs. 147.4 crore, a 975.0% increase from Q1 FY26.
- Earnings Per Share (EPS) for Q1 FY27 stood at Rs. 114.9, rising 975.0% year-over-year.
- EBITDA Margin expanded to 35.5% in Q1 FY27, an increase of 2150 basis points from 14.0% in Q1 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Income
650.1 Rs. crore
116.3%
EBITDA
231.1 Rs. crore
448.2%
EBITDA Margin
35.5%
2150 bps
Profit Before Tax
197.5 Rs. crore
1036.7%
Profit After Tax
147.4 Rs. crore
975.0%
PAT Margin
22.7%
1811 bps
EPS (Rs.)
114.9 Rs.
975.0%
🏢 How This Affects the Company
The company's performance in Q1 FY27, driven by Commercial Products and pipeline projects, aligns with management expectations for a good start to the year. Increased customer engagement on broader capability-led discussions suggests potential for long-term partnerships.
Substantial increases in Total Income, EBITDA, and Profit After Tax indicate improved financial performance compared to the prior year. Expanded EBITDA and PAT margins contribute to stronger profitability metrics.
Management stated ongoing significant investments in Capex projects are proceeding as planned, with expectations for further investment intensity based on available opportunities.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported earnings per share of Rs. 114.9 for Q1 FY27, which indicates increased profitability.
🔍
Management Signal
Management indicates a focus on consistent delivery, customer confidence, long-term partnerships, and increasing investment intensity based on opportunities.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — observe sustained YoY growth in income and profit.
Updates on Capex projects — monitor progress and impact on future capacity.
Earnings call transcript — review detailed management commentary on business segments.
LOW RISK
The filing indicates strong financial performance and positive management outlook, with no new risks identified.
💡 Investor Takeaway
Neuland Laboratories reported Q1 FY27 Total Income of Rs. 650.1 crore, a 116.3% YoY increase. Profit After Tax surged 975.0% to Rs. 147.4 crore, with EBITDA Margin at 35.5%, up 2150 bps YoY, indicating robust profitability.
⚖️ Strengths & Concerns
✅ Positives
- Profit After Tax (PAT) for Q1 FY27 increased by 975.0% to Rs. 147.4 crore compared to Rs. 13.7 crore in Q1 FY26.
- EBITDA margin expanded to 35.5% in Q1 FY27, a 2150 basis points improvement from 14.0% in Q1 FY26.
⚠️ Concerns
- Total Income decreased by 17.6% to Rs. 650.1 crore in Q1 FY27 compared to Rs. 788.7 crore in Q4 FY26.
- EBITDA decreased by 27.6% to Rs. 231.1 crore in Q1 FY27 compared to Rs. 319.4 crore in Q4 FY26.
📅 Company Track Record
In Q4 FY26, Neuland Labs reported Total Income of Rs. 788.7 crore and PAT up 666.3% YoY. The company approved a Rs. 3.4/share dividend and a Rs. 143.4 crore capacity expansion on May 12, 2026, indicating ongoing investment in growth.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Neuland Laboratories' Total Income for Q1 FY27?
Neuland Laboratories reported a Total Income of Rs. 650.1 crore for the quarter ended June 30, 2026, which is an increase of 116.3% compared to Q1 FY26.
What was the Profit After Tax (PAT) for Neuland Laboratories in Q1 FY27?
The Profit After Tax for Neuland Laboratories in Q1 FY27 was Rs. 147.4 crore, representing a 975.0% increase from Rs. 13.7 crore in Q1 FY26.
How did Neuland Laboratories' EBITDA perform in Q1 FY27?
Neuland Laboratories' EBITDA for Q1 FY27 was Rs. 231.1 crore, showing a 448.2% growth compared to Rs. 42.1 crore in Q1 FY26.
What was the EBITDA Margin for Neuland Laboratories in Q1 FY27?
The EBITDA Margin for Neuland Laboratories in Q1 FY27 was 35.5%, an improvement of 2150 basis points from 14.0% in Q1 FY26.
What was the Earnings Per Share (EPS) for Neuland Laboratories in Q1 FY27?
The Earnings Per Share (EPS) for Neuland Laboratories in Q1 FY27 was Rs. 114.9, which is a 975.0% increase from Rs. 10.7 in Q1 FY26.
Questions based on this BSE filing only. For information purposes.